Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

BATOLISA Ended

2024-513529-21-00 Lipedema 6 2025-01-24
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended

2023-507193-40-00 Moderate to Severe Plaque Psoriasis 5 2025-01-16
A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal… Ended

2024-518453-41-00 Hereditary angioedema (HAE) 3 2024-12-30
An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates Ended

2024-513495-17-00 Dermatitis atopic 3 2024-11-20
Investigator initiated clinical trial of dantrolene as a treatment for Darier disease Ended

2024-519201-36-00 Darier disease 4 2024-11-07
A prospective, randomized, evaluator- and subject blinded, multi-center investigation to assess efficacy and safety of three different dosag… Ended

2024-512349-17-00 Moderate and severe horizontal forehead lines. 4 2024-11-06
A Phase 2, multicentre, open-label study of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris Ended

2024-513305-32-00 Palmoplantar Pustulosis 4 2024-10-29
A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of all… Ended

2024-518757-42-00 Difficult-to-heal venous leg ulcers 9 2024-10-28
A clinical trial to evaluate safety, efficacy, and tolerability of abrocitinib in subjects with chronic hand eczema. Ended

2023-504539-42-00 Moderate to severe chronic hand eczema 4 2024-10-20
An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Val… Ended

2024-516184-87-00 not applicable (submitted trial is a bioavailability st 2 2024-10-18
Evaluation of efficacy and safety of 0.1% mometasone furoate cutaneous emulsion compared to its active ingredient-free base and a comparator… Ended

2024-511583-82-00 Plaque psoriasis 5 2024-10-08
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 hidradenitis suppurativa (HS) 5 2024-10-02
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended

2024-511225-64-00 Alopecia areata 4 2024-09-18
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended

2024-513647-86-00 Patients displaying a non-classified, severe and resist 4 2024-09-09
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera… Ended

2023-505433-27-00 Atopic Dermatitis 5 2024-08-13
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PHASE I TRIAL TO INVESTIGATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING TO… Ended

2024-512893-86-00 Actinic keratosis 3 2024-08-06
GuARD: GR1014 cutaneous gel Against Radiation Dermatitis Ended

2023-508728-36-00 Radiation-induced dermatitis (radiodermatitis) 4 2024-07-26
Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis Ended

2023-509079-18-00 Plaque Psoriasis 3 2024-07-22
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczem… Ended

2023-504298-19-00 Chronic Hand Eczema 4 2024-07-18
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment… Ended

2023-509738-20-00 Plaque Psoriasis 6 2024-07-11
A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended

2023-508377-82-00 Hidradenitis Suppurativa (HS) 10 2024-06-27
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations … Ended

2024-511196-15-00 Hereditary angioedema (HAE) 3 2024-06-13